Abstract

BackgroundMumps, also known as Sudden parotitis, is a viral disease whose main source of infection is the sick/infected person. It posed a serious public health threat in Poland before the introduction of mandatory vaccination. In 2003, Poland introduced the Immunization Program, which included a two-dose vaccination against mumps as part of the MMR (measles, mumps and rubella) vaccine for all children.ObjectiveThe study aimed to assess the epidemiological situation of mumps in Poland in 2022 compared to previous years, including an analysis of the impact of the COVID-19 pandemic.Material and methodsThe analysis of the epidemiological situation of mumps in Poland in 2022 was based on the interpretation of data published in the annual bulletin: "Infectious Diseases and Poisonings in Poland in 2022" and "Vaccinations in Poland in 2022".ResultsIn 2022, 922 cases of mumps were registered in Poland. This was a 90.5% increase compared to 2021 when 484 cases were recorded. The total incidence was 2.4 per 100,000 residents, 84.6% higher than in 2021. The highest incidence of 3.4 per 100 000 residents was registered in the Mazowieckie voivodeship, and the lowest, as in the previous year, was 1.0/100 000 residents in the Dolnośląskie voivodeship. The highest incidence (12.9/100 000) was recorded in children aged 0-4 and 5-9 (16.1/100 000). The incidence in men (3.0/100 000) was higher than in women (1.9/100 000). In 2022, the number of hospitalizations for mumps in Poland was 20, an increase of 122.2% compared to 2021, when 9 people were hospitalized.ConclusionsThe year 2022 showed an overall upward trend in registered mumps cases. The decrease in the number of mumps cases in 2021 was a result of the ongoing pandemic. The restrictions implemented during the pandemic period contributed to a decrease in the number of cases of various droplet-transmitted diseases, including mumps. Still, the observed number of mumps cases in 2022 remains below levels observed during the pre-pandemic COVID-19 period (2019).

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.